R L Murphy
Affiliation: Northwestern University
- Defining the toxicity profile of nevirapine and other antiretroviral drugsRobert L Murphy
Northwestern University, Chicago, IL 60611, USA
J Acquir Immune Defic Syndr 34:S15-20. 2003..These measures may help to identify potential toxicities better and any risk factors that predispose patients to the development of treatment-related side-effects...
- Clinical and biological insights in HIV-associated cardiovascular disease in the era of highly active antiretroviral therapyRobert L Murphy
Division of Infectious Diseases, Northwestern University, Chicago, Illinois, USA
AIDS 17:S1-3. 2003
- Switch studies: a reviewR L Murphy
Northwestern University, Chicago, IL 60611 USA
HIV Med 3:146-55. 2002..Resolution of lipodystrophy symptoms has not been demonstrated objectively, perhaps because of insufficient follow-up and/or the role of NRTIs in this syndrome...
- Change to atazanavir/ritonavir treatment improves lipids but not endothelial function in patients on stable antiretroviral therapyRobert L Murphy
Northwestern University Center for Global Health, Northwestern University, Chicago, Illinois 60611, USA
AIDS 24:885-90. 2010..The protease inhibitor atazanavir has an advantageous lipid profile; we studied its effects on arterial function and other metabolic and inflammatory cardiovascular disease risk factors...
- Stavudine, lamivudine plus novel protease inhibitor therapy in antiretroviral-naive HIV-infected individuals treated for 24 weeksR L Murphy
HIV Treatment Unit, Northwestern University Medical School, Chicago, Illinois, USA
Antivir Ther 4:85-7. 1999..The HIV-1 RNA had decreased to <400 copies/ml in 94% of patients and CD4 cell count had increased by approximately 160 cells/mm3 at 24 weeks. The regimen was well tolerated and merits further study...
- ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naive adults with HIV-1 infection: 48-week resultsR L Murphy
Department of Medicine, Northwestern University, Chicago, IL 60611, USA
AIDS 15:F1-9. 2001..The activity and durable suppression of HIV-1 observed in this study is probably attributable to the observed tolerability profile and the achievement of high ABT-378 plasma concentrations...
- Antiviral effect and pharmacokinetic interaction between nevirapine and indinavir in persons infected with human immunodeficiency virus type 1R L Murphy
Division of Infectious Diseases, Department of Medicine, Northwestern University, Chicago, IL 60611, USA
J Infect Dis 179:1116-23. 1999..Plasma HIV RNA values were </=20 copies/mL in 10 of 17 (58.8%) subjects at 58 weeks or last visit. These data suggest that indinavir dosing should be dependent on drug exposure and not on cotherapy with nevirapine...
- Treatment with amprenavir alone or amprenavir with zidovudine and lamivudine in adults with human immunodeficiency virus infection. AIDS Clinical Trials Group 347 Study TeamR L Murphy
Division of Infectious Diseases, Northwestern University Medical School, Illinois, Chicago, IL 60611, USA
J Infect Dis 179:808-16. 1999..04 log10 copies/mL, and 17 (63%) of 27 evaluable subjects had <500 HIV RNA copies/mL. Treatment with amprenavir, zidovudine, and lamivudine together reduced the levels of HIV RNA significantly more than did amprenavir monotherapy...
- Stavudine-based multiple agent combinations: initial studies and ongoing comparative trialsR L Murphy
AIDS Treatment Unit, Northwestern University, Chicago, IL 60611, USA
Antivir Ther 3:69-73. 1998..Results of these studies should help to define additional first-line treatment options and strategies for sequencing antiretroviral treatment regimens...
- Seven-year efficacy of a lopinavir/ritonavir-based regimen in antiretroviral-naïve HIV-1-infected patientsRobert L Murphy
Northwestern University, Chicago, Illinois, USA
HIV Clin Trials 9:1-10. 2008..Evaluate efficacy and tolerability of lopinavir/ritonavir (LPV/r) plus stavudine and lamivudine long term in antiretroviral-naïve patients...
- Dose-ranging, randomized, clinical trial of atazanavir with lamivudine and stavudine in antiretroviral-naive subjects: 48-week resultsRobert L Murphy
Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA
AIDS 17:2603-14. 2003..To compare the efficiency and safety of atazanavir and nelfinavir in antiretroviral-naive patients...
- Safety, tolerability, and mechanisms of antiretroviral activity of pegylated interferon Alfa-2a in HIV-1-monoinfected participants: a phase II clinical trialDavid M Asmuth
Division of Infectious Diseases, University of California Davis Medical School, 4150 V Street, Sacramento, CA 95817 1460, USA
J Infect Dis 201:1686-96. 2010..To our knowledge, the antiviral activity of pegylated interferon alfa-2a has not been studied in participants with untreated human immunodeficiency virus type 1 (HIV-1) infection but without chronic hepatitis C virus (HCV) infection...
- Transient viremia in HIV-infected patients and use of plasma preparation tubesValentina Stosor
Division of Infectious Diseases, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA
Clin Infect Dis 41:1671-4. 2005..We caution clinicians against the routine use of plasma preparation tubes for collection of blood samples for HIV-1 level 1 quantification...
- Clinical applications and availability of CD4+ T cell count testing in sub-Saharan AfricaBabafemi O Taiwo
Division of Infectious Diseases, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA
Cytometry B Clin Cytom 74:S11-8. 2008....
- Management of antiretroviral failure and resistance in developing countriesClaudia Hawkins
Northwestern University, Chicago, Illinois 60611, USA
Curr Opin HIV AIDS 4:538-44. 2009..This review focuses on the identification and management of these complex patients in settings with limited antiretroviral drug options and resources...
- Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in NigeriaClaudia A Hawkins
Northwestern University, Chicago, IL 60611, USA
J Acquir Immune Defic Syndr 52:228-34. 2009..Patterns and frequency of antiretroviral drug resistance mutations observed in these countries may differ from those in the developed world, where HIV-1 subtype B predominates...
- Antiviral activity and tolerability of amdoxovir with zidovudine in a randomized double-blind placebo-controlled study in HIV-1-infected individualsRobert L Murphy
Northwestern University, Feinberg School of Medicine, Chicago, IL, USA
Antivir Ther 15:185-92. 2010..Here, we aimed to assess the short-term tolerability and antiviral activity of amdoxovir in combination with reduced and standard doses of zidovudine...
- Assessing the viorologic and adherence benefits of patient-selected HIV treatment partners in a resource-limited settingBabafemi O Taiwo
Division of Infectious Diseases, Feinberg School of Medicine, Northwestern University, 645 N Michigan Avenue, Suite 900, Chicago, IL 60611, USA
J Acquir Immune Defic Syndr 54:85-92. 2010..To determine the efficacy of patient-selected treatment partners on virologic and adherence outcomes during first-line antiretroviral therapy...
- Abacavir/lamivudine fixed-dose combination antiretroviral therapy for the treatment of HIVChad J Achenbach
Feinberg School of Medicine and Center for Global Health, Northwestern University, Chicago, USA
Adv Ther 27:1-16. 2010..We reviewed abacavir/lamivudine as a treatment for HIV and discussed limitations of its use due to these controversial issues...
- Novel antiretroviral combinations in treatment-experienced patients with HIV infection: rationale and resultsBabafemi Taiwo
Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA
Drugs 70:1629-42. 2010....
- The pharmacokinetics of amprenavir, zidovudine, and lamivudine in the genital tracts of men infected with human immunodeficiency virus type 1 (AIDS clinical trials group study 850)Arlene S Pereira
Division of Infectious Diseases, University of North Carolina School of Medicine, Chapel Hill, North Carolina 27599, USA
J Infect Dis 186:198-204. 2002..The antiretroviral effect of APV monotherapy was related to APV concentrations...
- Extended antiretroviral treatment interruption in HIV-infected patients with long-term suppression of plasma HIV RNAC J Achenbach
Division of Infectious Diseases, The Feinberg School of Medicine, Northwestern University, Chicago, IL, USA
HIV Med 6:7-12. 2005..Evaluation of extended treatment interruption (TI) in chronic HIV infection among patients successfully treated with antiretroviral therapy...
- Long-term follow-up of HIV-infected individuals who have significant increases in CD4+ cell counts during antiretroviral therapySusan L Koletar
Division of Infectious Diseases, Ohio State University, Columbus, OH 43210, USA
Clin Infect Dis 39:1500-6. 2004..Descriptions of the durability and consequences of immune reconstitution in patients who start highly active antiretroviral therapy (HAART) while severely immunosuppressed are limited...
- Antiretroviral therapy for advanced naïve HIV-infected patients: current status and comparison of two different management strategiesRobert L Murphy
Division of Infectious Diseases, Northwestern University, Chicago, Illinois 60611, USA
J Acquir Immune Defic Syndr 46:S1-2. 2007
- Reviving protease inhibitors: new data and more optionsRobert L Murphy
The Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA
J Acquir Immune Defic Syndr 33:S43-52; quiz S53, S55-6. 2003
- Class-sparing regimens for initial treatment of HIV-1 infectionSharon A Riddler
University of Pittsburgh, Pittsburgh, USA
N Engl J Med 358:2095-106. 2008..The alternative regimen of lopinavir-ritonavir plus efavirenz may prevent toxic effects associated with NRTIs...
- Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trialRoy M Gulick
Cornell HIV Clinical Trials Unit, Division of International Medicine and Infectious Diseases, Weill Medical College of Cornell University, New York, NY, USA
JAMA 296:769-81. 2006..Three-drug antiretroviral regimens are standard of care for initial treatment of human immunodeficiency virus 1 (HIV-1) infection, but a 4-drug regimen could improve antiretroviral activity and be more effective than a 3-drug regimen...
- Endothelial function in human immunodeficiency virus-infected antiretroviral-naive subjects before and after starting potent antiretroviral therapy: The ACTG (AIDS Clinical Trials Group) Study 5152sFrancesca J Torriani
Infection Prevention and Clinical Epidemiology Unit, University of California San Diego, 200 West Arbor Drive, MC 8951, San Diego, California 92103, USA
J Am Coll Cardiol 52:569-76. 2008..This study evaluated the effects of 3 class-sparing antiretroviral therapy (ART) regimens on endothelial function in human immunodeficiency virus (HIV)-infected subjects participating in a randomized trial...
- Greater viral rebound and reduced time to resume antiretroviral therapy after therapeutic immunization with the ALVAC-HIV vaccine (vCP1452)Brigitte Autran
UPMC Univ Paris 06, UMR_543, France
AIDS 22:1313-22. 2008..Evaluate immunogenicity and clinical efficacy of two immunization strategies with the ALVAC-HIV-recombinant canarypox vaccine (vCP1452) in treated HIV-infected patients...
- Characteristics of patients with cytomegalovirus retinitis in the era of highly active antiretroviral therapyDouglas A Jabs
Wilmer Eye Institute, 550 North Broadway, Suite 700, Baltimore, Maryland 21205, USA
Am J Ophthalmol 133:48-61. 2002..To describe the characteristics of patients with AIDS and cytomegalovirus retinitis in the era of highly active antiretroviral therapy (HAART)...
- A randomized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1-infected patientsRemko van Leeuwen
International Antiviral Therapy Evaluation Center, Academic Medical Center, Amsterdam, The Netherlands
AIDS 17:987-99. 2003..To compare one protease inhibitor (PI)-based and two PI-sparing antiretroviral therapy regimens...
- The pavia consensus statementPaul A Volberding
University of California, San Francisco, USA
AIDS 17:S170-9. 2003
- Persistent abnormalities in lymphoid tissues of human immunodeficiency virus-infected patients successfully treated with highly active antiretroviral therapyTimothy W Schacker
Department of Medicine, University of Minnesota, MMC 250, 516 Delaware Street, Minneapolis MN 55455, USA
J Infect Dis 186:1092-7. 2002....
- Comparison of sequential three-drug regimens as initial therapy for HIV-1 infectionGregory K Robbins
Harvard Medical School, Boston, USA
N Engl J Med 349:2293-303. 2003..The optimal sequencing of antiretroviral regimens for the treatment of infection with human immunodeficiency virus type 1 (HIV-1) is unknown. We compared several different antiretroviral treatment strategies...
- Influence of filgrastim (granulocyte colony-stimulating factor) on human immunodeficiency virus type 1 RNA in patients with cytomegalovirus retinitisMichael Davidson
Center for Clinical Trials, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD 21205, USA
J Infect Dis 186:1013-8. 2002..87 (P=.12) and respective log mean rates of change per month of -0.08 versus -0.21 (P=.08). This latter difference has borderline statistical significance, which suggests that filgrastim may reduce the decline of HIV-1 RNA loads...
- Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infectionRoy M Gulick
Weill Medical College of Cornell University, New York, USA
N Engl J Med 350:1850-61. 2004....
- Potent antiviral effect of reverset in HIV-1-infected adults following a single oral doseLieven J Stuyver
Pharmasset, Inc, Tucker, GA, USA
Antivir Ther 9:529-36. 2004..A single 10 mg RVT dose resulted in a viral load drop of 0.61 +/- 0.05 log10 providing evidence that a viral strain with the indicated genotype is susceptible to RVT...
- Safety and antiviral activity at 48 weeks of lopinavir/ritonavir plus nevirapine and 2 nucleoside reverse-transcriptase inhibitors in human immunodeficiency virus type 1-infected protease inhibitor-experienced patientsConstance A Benson
Department of Medicine, University of Colorado Health Sciences Center, 4200 E 9th Avenue, B 168, Denver, CO 80262, USA
J Infect Dis 185:599-607. 2002..Mean CD4 cell counts increased by 125 cells/muL. Three patients discontinued therapy for drug-related adverse events...
- Challenges for the clinical development of new nucleoside reverse transcriptase inhibitors for HIV infectionMark A Wainberg
McGill University AIDS Center, Lady Davis Institute Jewish General Hospital, Montreal, QC, Canada
Antivir Ther 10:13-28. 2005..The successful development of new NRTIs will depend upon a thorough appreciation of these many and complex issues, not only among those involved in the design of clinical studies, but also those contributing to their review and conduct...
- Risk factors for mortality in patients with AIDS in the era of highly active antiretroviral therapyDouglas A Jabs
Department of Ophthalmology, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
Ophthalmology 112:771-9. 2005..To evaluate risk factors for mortality among patients with AIDS in the era of highly active antiretroviral therapy (HAART), particularly the effect of cytomegalovirus (CMV)...
- A phase II clinical study of the long-term safety and antiviral activity of enfuvirtide-based antiretroviral therapyJacob P Lalezari
Quest Clinical Research, San Francisco, CA 94115, USA
AIDS 17:691-8. 2003..Secondary objectives included the determination of enfuvirtide pharmacokinetics and antiviral activity and the immunological response to the enfuvirtide-containing regimen...
- The safety, plasma pharmacokinetics, and antiviral activity of subcutaneous enfuvirtide (T-20), a peptide inhibitor of gp41-mediated virus fusion, in HIV-infected adultsJ Michael Kilby
UAB HIV Outpatient Clinic, University of Alabama at Birmingham, CCB 245A, 908 20th Street South, Birmingham, AL 35294 2050, USA
AIDS Res Hum Retroviruses 18:685-93. 2002..Injection site reactions were common but generally mild. These results indicate that enfuvirtide is a promising new therapeutic agent for HIV-infected patients, including those with prior antiretroviral treatment...
- Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1Frank van Leth
International Antiviral Therapy Evaluation Center, Division of Infectious Diseases, Tropical Medicine, and AIDS, Department of Internal Medicine, Academic Medical Center, University of Amsterdam, The Netherlands
PLoS Med 1:e19. 2004..We analysed whether lipid changes differed between the two most commonly used NNRTIs, nevirapine (NVP) and efavirenz (EFV)...
- Genetic and functional analysis of full-length human immunodeficiency virus type 1 env genes derived from brain and blood of patients with AIDSAsa Ohagen
Department of Cancer Immunology and AIDS, Dana Farber Cancer Institute, Boston, Massachusetts, USA
J Virol 77:12336-45. 2003....
- Long-term safety and durable antiretroviral activity of lopinavir/ritonavir in treatment-naive patients: 4 year follow-up studyCharles Hicks
Duke University Medical Center, Durham, North Carolina, 27710, USA
AIDS 18:775-9. 2004..Results of long-term therapy with LPV/r-based regimens have not been previously reported. This study describes the 4-year (204-week) safety and antiretroviral activity of LPV/r-based treatment in antiretroviral-naive individuals...
- Clinical, microbiological, and immunological characteristics in HIV-infected subjects at risk for disseminated Mycobacterium avium complex disease: an AACTG studyRob Roy MacGregor
Infectious Diseases Division, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
AIDS Res Hum Retroviruses 21:689-95. 2005..MAC-specific T cell responses apparently develop and persist during DMAC, but are dysfunctional or too infrequent to prevent persistence...
- Incidence of pancreatitis in HIV-1-infected individuals enrolled in 20 adult AIDS clinical trials group studies: lessons learnedRonald B Reisler
Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD 21201, USA
J Acquir Immune Defic Syndr 39:159-66. 2005..To report on the incidence of clinical- and laboratory-defined pancreatitis in HIV-1-infected individuals treated with antiretrovirals (ARVs)...